ArticleSmall methods2026
High-Throughput Volumetric Mapping Facilitated by Active Tissue SHRINK.
Article in Small methods, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Comprehensive visualization of tissue architecture in large organs such as the brain is crucial for understanding functional relationships across key tissue regions. However, the large size of whole organs makes it challenging to image their entirety with subcellular resolution, often requiring prolonged imaging sessions, volume reconstruction, and compromises in spatial coverage. Here, Scalable Hydrogel-embedded Rapid Imaging of tissue NetworK (SHRINK) is reported to address this challenge through active tissue shrinkage and clearing. Utilizing the identified hydrogel network to preserve the spatial pattern of proteins in situ and remove the uncrosslinked biomolecules to create space, it is shown that SHRINK isotropically drives the reduction of sample sizes down to 16% of their original volume while maintaining high cellular and tissue-level integrity in a reversible manner. The size reduction and the corresponding 3D concentrating of the biomolecules render a more than sixfold enhancement for throughput and signal respectively, which addresses a key bottleneck for the stimulated Raman scattering (SRS) microscopy, ideal for 3D, label-free and super-multiplex tissue mapping. It is further demonstrated that SHRINK-SRS achieves organ-scale mapping of brain, intestine, heart, and kidney tissues. SHRINK offers a powerful approach to overcome traditional imaging barriers, enabling rapid and detailed visualization of large organs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.